Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
August 09, 2022 08:00 ET
|
Prelude Therapeutics, Inc.
Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA) Clinical data readouts and next steps for the PRMT5...